Risk factors for the failure of first-line PARP inhibitor maintenance therapy in patients with advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration Study (GORILLA-3004).
Nam Kyeong KimYeorae KimHee Seung KimSoo Jin ParkDong Won HwangSung-Jong LeeJi Geun YooSuk-Joon ChangJoo-Hyuk SonTae-Wook KongJeeyeon KimSeung-Hyuk ShimA Jin LeeDong Hoon SuhYoo-Young LeePublished in: Cancer medicine (2023)
High pre-PARPi serum CA-125 levels, non-HGSC histology, NAC, and no BRCA mutation might be risk factors for early failure of first-line PARPi maintenance therapy. In women with BRCA mutations, high pre-PARPi serum CA-125 levels, which represent a large tumor burden before PARPi, were the only independent risk factor for poor PFS.